CARM · As filed with the SEC
Carisma Therapeutics cash flow statement, by quarter
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Unaudited Consolidated Statements of Cash Flows · USD thousands
| USD thousands | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024† 3 months ended Sep 30, 2024 | Q2 2024† 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023† 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | — | — | — | — | (11,162)† | (18,978) | (20,958)† |
| Net income (loss) | — | — | (9,266,000) | — | — | — | — | — |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization expense | — | — | 661,000 | — | — | — | 1,693,000 | — |
| Stock-based compensation expense | — | — | 508,000 | — | — | — | 1,057,000 | — |
| Reduction in the operating right of use assets | — | — | 877,000 | — | — | — | 1,360,000 | — |
| Amortization of debt discount | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Change in fair value of derivative liability | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Accretion on marketable securities | — | — | — | 0† | 0† | 0† | 0 | 32† |
| Write-off of property and equipment | — | — | — | 288† | 7† | 0† | 67 | 0† |
| Write-off of deferred financing costs | — | — | 208,000 | — | — | — | — | — |
| Gain (loss) on sale of property and equipment | — | — | (113,000) | — | — | — | — | — |
| Non-cash interest expense | — | — | 19,000 | — | — | — | 236,000 | — |
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | — | — | 3,015,000 | — | — | — | (1,572,000) | — |
| Accounts payable | — | — | 1,170,000 | — | — | — | (1,826,000) | — |
| Accrued expenses | — | — | (2,743,000) | — | — | — | (2,933,000) | — |
| Deferred revenue | — | — | (3,729,000) | — | — | — | (224,000) | — |
| Operating lease liabilities | — | — | (707,000) | — | — | — | (1,355,000) | — |
| Other long term liabilities | — | — | 33,000 | — | — | — | 50,000 | — |
| Net cash used in operating activities | — | — | (10,067,000) | — | — | — | (22,425,000) | — |
| Cash flows from investing activities: | ||||||||
| Purchase of marketable securities | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Proceeds from the sale of marketable securities | — | — | — | 0† | 0† | 0† | 0 | 11,000† |
| Proceeds from the sale of property and equipment | — | — | 524 | — | — | — | — | — |
| Purchases of property and equipment | — | — | 0 | — | — | — | (17,000) | — |
| Net cash provided by (used in) investing activities | — | — | 524,000 | — | — | — | (17,000) | — |
| Cash flows from financing activities: | ||||||||
| Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Payment of reverse recapitalization finance costs | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Proceeds from the issuance of common stock in pre-closing financing | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Payment of principal related to finance lease liabilities | — | — | (304,000) | — | — | — | (1,319,000) | — |
| Proceeds from failed sale-leaseback arrangement | — | — | 0 | — | — | — | 686,000 | — |
| Payment of finance liability from failed sale-leaseback arrangements | — | — | (327,000) | — | — | — | (303,000) | — |
| Payment of deferred financing costs | — | — | — | 0† | — | — | — | 0† |
| Proceeds from issuance of convertible promissory note | — | — | — | — | — | — | — | 0† |
| Proceeds from the exercise of stock options | — | — | 5,000 | — | — | — | 2,000 | — |
| Sale of common stock under Open Market Sale Agreement, net of issuance costs | — | — | 0 | — | — | — | 2,286,000 | — |
| Net cash (used in) provided by financing activities | — | — | (626,000) | — | — | — | 1,352,000 | — |
| Net decrease in cash, cash equivalents and restricted cash | — | — | (10,169,000) | — | — | — | (21,090,000) | — |
| Cash, cash equivalents, and restricted cash at beginning of the year | 1,999,000 | 7,740,000 | 17,909,000 | 26,881,000 | 40,362,000 | 56,515,000 | 77,605,000 | 83,162,000 |
| Cash, cash equivalents and restricted cash at end of the period | 2,777,000 | 1,999,000 | 7,740,000 | 17,909,000 | 26,881,000 | 40,362,000 | 56,515,000 | 77,605,000 |
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | — | — | 33,000 | — | — | — | 50,000 | — |
| Supplemental disclosure of non-cash financing and investing activities: | ||||||||
| Conversion of convertible preferred stock and non-controlling interests upon Merger | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Conversion of convertible promissory note, accrued interest and derivative liability upon Merger | — | — | — | 0† | 0† | 0† | 0 | 0† |
| Reverse recapitalization costs in accrued expenses | — | — | — | — | — | 0† | 0 | — |
| Unrealized gain on marketable securities | — | — | — | 0† | 0† | 0† | 0 | (373)† |
| Right-of-use assets obtained in exchange for new operating lease liabilities | — | — | 836,000 | — | — | — | 4,337,000 | — |
| Right-of-use assets obtained in exchange for new finance lease liabilities | — | — | 0 | — | — | — | 2,470,000 | — |
| Allocation of debt proceeds to derivative liability | — | — | — | — | — | — | — | 0† |
| Property and equipment in accounts payable | — | — | 0 | — | — | — | 59 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.